Magdalena aiming to submit Investigational New Drug (IND) application in 2025 to the FDA for a next-generation psychoactive prescription drug candidate for potential mental health indications such as ...
CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a clinical-stage biotech company with a market capitalization of $28 million, announced today positive outcomes from its Phase 1 ...
On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a ...
A nasal vaccine for COVID-19—based on technology developed at Washington University in St. Louis—is poised to enter a phase 1 ...
Affinia Therapeutics, a gene therapy company with a pipeline of adeno-associated virus (AAV) gene therapies for devastating ...
Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data ...
PDS Biotechnology (PDSB) reaffirmed the Company’s guidance of initiating its VERSATILE-003 Phase 3 clinical trial of Versamune HPV plus ...
A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...
Preparing to Initiate Clinical Development in Patients with Hematologic Malignancies in the First Quarter of 2025Series B Financing Funds ...
The U.S. Food and Drug Administration (FDA has cleared the investigational new drug (IND) application for Allogene Therapeutics’ ALLO-329, an investigational allogenic CAR-T cell therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback